Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Five Spanish Hospitals start international phase III clinical trial with H5N1 influenza pandemic vaccine

05.05.2006


Both governments and the scientific community are mobilised to face the threat of a possible pandemic provoked by avian influenza. Whereas there is no need to alarm the population, we must design tools in order to fight influenza in case it develops. According to historical data and to the high genetic variability of influenza virus, the development of this pandemic is only a matter of time and that the appropriate circumstances are given.



The H5N1 virus, which affects the European fowl, has already evidenced that it could successfully break the human barrier. This is the reason why H5N1 is the best candidate to establish the bases of the development of pandemic vaccines. Five large national hospitals will participate in the first study with a H5N1 influenza pandemic vaccine held in Spain. Our specialists are working in an international study, with the participation of 7 countries, in order to assess the possible side effects and immunogenicity of this vaccine, developed by GlaxoSmithKline (GSK), in individuals over 18 years.

A total of 5,052 individuals will participate in this study, 1,500 of which will be recruited in Spain. The five Spanish centres are Hospital 12 de Octubre, Hospital Clínico San Carlos and Hospital de La Princesa in Madrid, and the centres Hospital Vall d’Hebrón and Hospital Clínic in Barcelona. People participating in the study will be randomly separated into two groups: 75% will receive two doses of influenza vaccine, and 25% will receive a dose of conventional influenza vaccine and a dose of placebo. The second dose will be administrated after 21 days after the first medical examination, and during the study, two more examinations will have place (days 43 and 180) and a telephone check (day 51). In 10% of volunteers, blood tests will be made in order to analyse the immune response triggered by the vaccine.


Furthermore, participants will fill in a monitoring card during the week after the administration of each dose, where the potential side effects that could appear, such as pain in the injection area or fever, frequent after any type of vaccination, will be noted. This study has been approved by the Ethics Committees of Clinical Research of the five hospitals and also by the Spanish Agency of Drugs and Health Products.

This vaccine is fractionated, since it only contains parts of the viral proteins which activate our immune system. Since no complete virus is administrated, it is impossible that this vaccine could cause influenza. The vaccine includes an adjuvant, similar to that used by GSK in the malaria vaccine that Hospital Clínic is testing in Mozambique, which enhances the immunogenic effects of the vaccine. The stimulation of the immune system caused by this adjuvant, has already proved successful as a part of a vaccine against conventional influenza, and permits to reduce the antigen concentration administered in each vaccination. In the hypothesis of a pandemic, we must take into account that it would be necessary to vaccinate a large amount of population, and the rhythm of production of vaccines is limited.

The efforts are focused in the development of strategies for vaccine production. Last, this vaccine has been produced following the recommendations of the WHO, so that the H5N1 virus has been recombined with the H1N1 Puerto Rico strain of 1934. This strain is highly stable and promotes the development of vaccines in chicken embryo.

The nomenclature of the several influenza virus identifies the variant they contain of the two more important genes involved in the infection. The Haemaglutinin (H) gene is related with the infectiousness and the virulence of the virus, whereas the Neuraminidase (N) gene determines the ability of progression of the infection. Genetic material of the virus is highly variable and it is found as fractionated single-strained RNA. Small changes in the H and N genes create viruses which cause the frequent annual influenza epidemic. When a large change is produced or a new version of the gene appears, an antigenic change is capable of triggering a worldwide epidemic, called pandemic.

Influenza virus with a pandemic potential could appear by direct transfer of an animal virus to humans, -as happened in the “Spanish Influenza” that in 1918 caused death to 5% of the world population- or by a genetic reassortment between human and animal viruses. Such genetic reassortment would have place in a host co-infected by two different viruses.

The probability that a pandemic human virus is generated is now low, but the risk exists, and it is increased when cases of animal flu are found in humas, such in the case of H5N1. The hundred of death cases documented until now can give an idea of the potential danger we are facing.

Furthermore, there are two circumstances that worsen this situation: this virus can mutate rapidly, and the fowl surviving the infection excrete the virus intensely through respiratory secretions and faeces during at least 10 days. Because of all this, it is important to make a both scientific and economic effort in order to obtain the best weapons to combat a possible definitive adaptation to humans of the H5N1 virus. In any case, this effort led by Spain, Germany, Holland, Sweden, Russia, France and Estonia will permit to improve the available tools in order to face this or future pandemics.

Àlex Argemí Saburit | alfa
Further information:
http://www.clinic.ub.es
http://www.idibaps.ub.edu

More articles from Health and Medicine:

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

nachricht Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Polymers Based on Boron?

18.01.2018 | Life Sciences

Bioengineered soft microfibers improve T-cell production

18.01.2018 | Life Sciences

World’s oldest known oxygen oasis discovered

18.01.2018 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>